Cargando…

Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?

Detalles Bibliográficos
Autores principales:	Andó, Giuseppe, Costa, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631728/ https://www.ncbi.nlm.nih.gov/pubmed/26677354 http://dx.doi.org/10.5114/pwki.2015.54007

Ejemplares similares

Clinical risk stratification for gastrointestinal hemorrhage: still no consensus
por: Wira, Charles, et al.
Publicado: (2008)

Is Retinal Assessment still Useful for Cardiovascular Risk Stratification in the Modern Era?
por: Kawasaki, Ryo
Publicado: (2022)

Commentary: Bunsen-Roscoe reciprocity – Is it still valid?
por: Anitha, Venugopal, et al.
Publicado: (2022)

Bleeding risk stratification in coronary artery surgery: the should-not-bleed score
por: Petricevic, Mirna, et al.
Publicado: (2021)

Validation of continuous cardiac output technologies: consensus still awaited
por: Cecconi, Maurizio, et al.
Publicado: (2009)

Is there still a role of nephrectomy in management of emphysematous pyelonephritis in today's era?
por: Shah, HN
Publicado: (2021)

Risk Stratification of Patients with Acute Coronary Syndrome
por: Bauer, Dávid, et al.
Publicado: (2021)

Reduction of hospitalisations and increased mortality for acute coronary syndromes during covid-19 era: Not all countries are equal
por: Spaccarotella, Carmen, et al.
Publicado: (2021)

Management of Structural Heart Disease and Acute Coronary Syndromes in the COVID-19 Pandemic
por: Giordano, Arturo, et al.
Publicado: (2020)

Role of biomarkers in risk stratification of acute coronary syndrome
por: Nagesh, C.M., et al.
Publicado: (2010)

Evidenced-Based Antithrombotic Therapy for Acute Coronary Syndromes
por: James, Stefan
Publicado: (2013)

Commentary: Mitral valve neo-chords, still a lot to learn!
por: Affonso da Costa, Francisco Diniz
Publicado: (2020)

Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention
por: Pham, Phuong-Anh, et al.
Publicado: (2011)

Is further improvement of the treatment of acute coronary syndromes still possible?
por: Dąbrowski, Marek Jerzy
Publicado: (2013)

Neonatal seizures therapy: we are still looking for the efficacious drug
por: Spagnoli, Carlotta, et al.
Publicado: (2013)

Cystatin C in the prognostic stratification of patients with an acute coronary syndrome
por: Lago, A Lopez, et al.
Publicado: (2007)

The role of biomarkers in the diagnosis and risk stratification of acute coronary syndrome
por: Chacko, Sanoj, et al.
Publicado: (2017)

Risk stratification and in-hospital outcome in patients with acute coronary syndrome
por: Bhalerao, Amitkumar V., et al.
Publicado: (2022)

The J Curve Phenomenon is Still Valid in the Era of Primary Revascularization
por: Lee, Hae-Young
Publicado: (2017)

About the complexity of adult onset Still’s disease… and advances still required for its management
por: Guilpain, Philippe, et al.
Publicado: (2017)

Everything Flows, Nothing Stays Still
por: Kölbel, Tilo, et al.
Publicado: (2021)

Radial Artery Access for Percutaneous Cardiovascular Interventions: Contemporary Insights and Novel Approaches
por: Scalise, Renato Francesco Maria, et al.
Publicado: (2019)

An observational comparison of distal radial and traditional radial approaches for coronary angiography
por: Bhambhani, Anupam, et al.
Publicado: (2020)

Bleeding after percutaneous coronary intervention: can we still ignore the obvious?
por: Shuvy, Mony, et al.
Publicado: (2014)

Is this (still) a man's world?
por: Metaxa, Victoria
Publicado: (2013)

Commentary: Are these times still unprecedented?
por: Chen, Jonathan M.
Publicado: (2021)

The STOP the Bleeding Campaign
por: Rossaint, Rolf, et al.
Publicado: (2013)

Role for Cystatin C–Based Risk Stratification for Patients After Acute Coronary Syndrome in the Era of High Sensitivity Cardiac Troponin Assays
por: Latta, Federica, et al.
Publicado: (2018)

Management of Acute Coronary Syndrome in the COVID Era
por: Bahuva, Ronak, et al.
Publicado: (2021)

Commentary: Hybrid palliation for hypoplastic left heart syndrome: Still feels like the tower of Babel
por: Pizarro, Christian
Publicado: (2020)

Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome
por: Kempf, Tibor, et al.
Publicado: (2013)

Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
por: Riccio, Gennaro, et al.
Publicado: (2016)

Comparing an Unstructured Risk Stratification to Published Guidelines in Acute Coronary Syndromes
por: Beck, Ann-Jean CC., et al.
Publicado: (2015)

Machine Learning Improves Risk Stratification After Acute Coronary Syndrome
por: Myers, Paul D., et al.
Publicado: (2017)

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome
por: Correa, Simon, et al.
Publicado: (2018)

Choosing Clinical Variables for Risk Stratification Post-Acute Coronary Syndrome
por: Myers, Paul D., et al.
Publicado: (2019)

Risk Stratification after an Acute Coronary Syndrome: Significance of Antithrombotic Therapy
por: Brazhnik, Victoria A., et al.
Publicado: (2021)

Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era?
por: Badakhshi, Harun, et al.
Publicado: (2018)

Do we still need supertrees?
por: Haeseler, Arndt von
Publicado: (2012)

Is faster still better in therapeutic hypothermia?
por: Howes, Daniel, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_f39788b437m58r70jssg942h8a